Myriad Genetics (MYGN) 10-Q 6 May 15 2015 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Mar. 31, 2015	Apr. 30, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Trading Symbol	MYGN
Entity Registrant Name	MYRIAD GENETICS INC
Entity Central Index Key	899923
Current Fiscal Year End Date	-24
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		69,451,234

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$55,209	$64,821
Marketable investment securities	79,224	121,641
Prepaid expenses	9,985	6,921
Inventory	29,359	23,919
Trade accounts receivable, less allowance for doubtful accounts of $7,730 at March 31, 2015 and $8,968 at June 30, 2014	92,195	81,869
Deferred taxes	13,460	6,445
Prepaid taxes		13,609
Other receivables	2,992	3,198
Total current assets	282,424	322,423
Equipment, leasehold improvements and property:
Equipment	97,595	80,685
Leasehold improvements	18,956	18,922
Property	20,075
Gross property, plant and equipment	136,626	99,607
Less accumulated depreciation	67,527	65,013
Net equipment, leasehold improvements and property	69,099	34,594
Long-term marketable investment securities	41,200	84,124
Long-term deferred taxes	407	3,180
Other assets	5,000	5,000
Intangibles, net	195,691	205,312
Goodwill	185,228	169,181
Total assets	779,049	823,814
Current liabilities:
Accounts payable	17,955	23,078
Accrued liabilities	47,879	56,410
Deferred revenue	1,339	1,090
Total current liabilities	67,173	80,578
Deferred grants	10,447
Unrecognized tax benefits	26,111	24,238
Other long term liabilities	6,420
Total liabilities	110,151	104,816
Stockholders' equity:
Preferred stock, $0.01 par value, authorized 5,000 shares, no shares issued and outstanding
Common stock, $0.01 par value, authorized 150,000 shares at March 31, 2015 and June 30, 2014,issued and outstanding 70,022 at March 31, 2015 and 73,497 at June 30, 2014	700	735
Additional paid-in capital	738,040	717,774
Accumulated other comprehensive loss	-7,560	-1,515
Accumulated (deficit)/retained earnings	-62,282	2,004
Total stockholders' equity	668,898	718,998
Total liabilities and stockholders' equity	$779,049	$823,814

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, except Share data, unless otherwise specified
Allowance for doubtful accounts	$7,730	$8,968
Preferred stock, par value	$0.01	$0.01
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, authorized	150,000,000	150,000,000
Common stock, issued	70,022,000	73,497,000
Common stock, outstanding	70,022,000	73,497,000

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Income and Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Molecular diagnostic testing	$172,978	$176,191	$516,634	$565,335
Pharmaceutical and clinical services	7,007	6,733	16,582	24,115
Total revenue	179,985	182,924	533,216	589,450
Costs and expenses:
Cost of molecular diagnostic testing	33,011	23,648	100,859	67,842
Cost of pharmaceutical and clinical services	3,282	2,961	8,152	10,379
Research and development expense	16,673	13,397	56,788	47,289
Selling, general, and administrative expense	91,279	87,631	269,415	242,752
Total costs and expenses	144,245	127,637	435,214	368,262
Operating income	35,740	55,287	98,002	221,188
Other income (expense):
Interest income	124	2,498	265	5,190
Other income (expense)	-298	-442	1,117	-1,066
Total other income (expense)	-174	2,056	1,382	4,124
Income before income taxes	35,566	57,343	99,384	225,312
Income tax provision	14,091	20,573	37,896	82,719
Net income	21,475	36,770	61,488	142,593
Earnings per share:
Basic	$0.30	$0.50	$0.85	$1.87
Diluted	$0.29	$0.48	$0.82	$1.82
Weighted average shares outstanding
Basic	70,696	73,821	71,985	76,173
Diluted	73,870	76,374	75,122	78,332
Comprehensive income:
Net income	21,475	36,770	61,488	142,593
Unrealized gain (loss) on available-for-sale securities, net of tax	-6	45	-282	583
Change in foreign currency translation adjustment, net of tax	-3,293	-672	-5,683	-280
Comprehensive income	$18,176	$36,143	$55,523	$142,896

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net income	$61,488	$142,593
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	18,389	8,291
Loss (gain) on disposition of assets	79	52
Share-based compensation expense	31,572	20,503
Bad debt expense	23,520	30,968
Accreted interest on note receivable		-3,337
Unrecognized tax benefits	1,873	2,923
Excess tax benefit from share-based compensation	-3,199	-5,109
Deferred income taxes	-1,043	1,827
Changes in operating assets and liabilities:
Prepaid expenses	-2,945	-837
Trade accounts receivable	-32,239	-17,307
Other receivables	955	-587
Prepaid taxes	13,609	-12,360
Inventory	-4,921	-10,395
Accounts payable	-6,400	-5,635
Accrued liabilities	-11,524	-2,233
Deferred revenue	242	-77
Net cash provided by operating activities	89,456	149,280
Cash flows from investing activities:
Capital expenditures for equipment and leasehold improvements	-21,905	-9,653
Acquisitions, net of cash acquired	-20,115	-223,531
Purchases of marketable investment securities	-55,069	-105,451
Proceeds from maturities and sales of marketable investment securities	140,802	339,865
Net cash provided by investing activities	43,713	1,230
Cash flows from financing activities:
Net proceeds from common stock issued under share-based compensation plans	25,635	47,156
Excess tax benefit from share-based compensation	3,199	5,109
Repurchase and retirement of common stock	-165,946	-222,014
Net cash used in financing activities	-137,112	-169,749
Effect of foreign exchange rates on cash and cash equivalents	-5,669	964
Net decrease in cash and cash equivalents	-9,612	-18,275
Cash and cash equivalents at beginning of period	64,821	104,073
Cash and cash equivalents at end of period	$55,209	$85,798

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Mar. 31, 2015
Basis of Presentation	-1	Basis of Presentation
	The accompanying condensed consolidated financial statements have been prepared by Myriad Genetics, Inc. (the “Company”) in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The condensed consolidated financial statements herein should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2014, included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2014. Operating results for the three and nine months ended March 31, 2015 may not necessarily be indicative of results to be expected for any other interim period or for the full year.
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	Certain reclassifications have been made to prior period amounts to conform to the current period presentation. For the nine months ended March 31, 2014, a reclassification of $1.0 million from proceeds from maturities and sales of marketable securities was made to the effect of foreign exchange rates on cash and cash equivalents in the condensed consolidated statement of cash flows and for the year ended June 30, 2014, a reclassification of $0.6 million from other receivables to trade accounts receivable on the condensed consolidated balance sheet to conform to the current-year presentation.

Marketable_Investment_Securiti

Marketable Investment Securities	9 Months Ended
	Mar. 31, 2015
Marketable Investment Securities	-2	Marketable Investment Securities
	The Company has classified its marketable investment securities as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive loss in stockholders’ equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at March 31, 2015 and June 30, 2014 were as follows:
	(In thousands)		Amortized		Gross		Gross			Estimated
			cost		unrealized		unrealized			fair value
					holding		holding
					gains		losses
	At March 31, 2015:
	Cash and cash equivalents:
	Cash		$	45,092	$	—	$	—		$	45,092
	Cash equivalents			10,117		—		—			10,117
	Total cash and cash equivalents			55,209		—		—			55,209
	Available-for-sale securities:
	Corporate bonds and notes			35,733		12		(11	)		35,734
	Municipal bonds			71,534		104		(22	)		71,616
	Federal agency issues			13,074		1		(1	)		13,074
	Total available-for-sale securities			120,341		117		(34	)		120,424
	Total cash, cash equivalents
	and available-for-sale securities		$	175,550	$	117	$	(34	)	$	175,633
	(In thousands)		Amortized		Gross		Gross			Estimated
			cost		unrealized		unrealized			fair value
					holding		holding
					gains		losses
	At June 30, 2014:
	Cash and cash equivalents:
	Cash		$	45,181	$	—	$	—		$	45,181
	Cash equivalents			19,639		1		—			19,640
	Total cash and cash equivalents			64,820		1		—			64,821
	Available-for-sale securities:
	Corporate bonds and notes			44,449		36		(11	)		44,474
	Municipal bonds			137,821		334		(3	)		138,152
	Federal agency issues			23,134		12		(7	)		23,139
	Total available-for-sale securities			205,404		382		(21	)		205,765
	Total cash, cash equivalents
	and available-for-sale securities		$	270,224	$	383	$	(21	)	$	270,586
	Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities are as follows at March 31, 2015:
	(In thousands)		Amortized		Estimated
			cost		fair value
	Cash		$	45,092	$	45,092
	Cash equivalents			10,117		10,117
	Available-for-sale:
	Due within one year			79,200		79,224
	Due after one year through five years			41,141		41,200
	Due after five years			—		—
			$	175,550	$	175,633

ShareBased_Compensation

Share-Based Compensation	9 Months Ended
	Mar. 31, 2015
Share-Based Compensation	-3	Share-Based Compensation
	The Company maintains a share-based compensation plan, the 2010 Employee, Director and Consultant Equity Incentive Plan, as amended (the “2010 Plan”), that has been approved by the Company’s shareholders. The 2010 Plan allows the Company, under the direction of the Compensation Committee of the Board of Directors, to make grants of stock options, restricted and unrestricted stock awards and other stock-based awards to employees, consultants and directors. On December 5, 2013, the shareholders approved an amendment to the 2010 Plan to set the number of shares available for grant to 3,500,000. At March 31, 2015, 1,801,462 shares were available for issuance. In addition, as of March 31, 2015, the Company may grant up to 4,400,795 additional shares under the 2010 Plan if options previously granted under the Company’s terminated 2003 Employee, Director and Consultant Option Plan are cancelled or expire without the issuance of shares of common stock by the Company.
	The number of shares, terms, and vesting period of awards under the 2010 Plan are determined by the Compensation Committee of the Board of Directors for each equity award. Stock options granted under the plan prior to December 5, 2012 generally vest ratably over four years and expire ten years from the grant date. Stock options granted after December 5, 2012 generally vest ratably over four years and expire eight years from the grant date. The exercise price of options granted is equivalent to the fair market value of the stock on the grant date. In September 2014, the Company began issuing restricted stock units (“RSUs”) which generally vest ratably over four years on the anniversary date of the grant in lieu of stock options to all employees and directors. The number of RSUs awarded to certain executive officers may be reduced if certain additional functional performance metrics are not met.
	Stock Options
	A summary of the stock option activity under the Company’s plans for the nine months ended March 31, 2015 is as follows:
			Number of		Weighted
			shares		average
					exercise
					price
	Options outstanding at June 30, 2014			14,238,183	$	23.3
	Options granted			1,000	$	37.17
	Less:
	Options exercised			1,144,275	$	20.2
	Options canceled or expired			343,161	$	25.7
	Options outstanding at March 31, 2015			12,751,747	$	23.51
	As of March 31, 2015, options to purchase 8,935,850 shares were vested and exercisable at a weighted average price of $22.55.
	As of March 31, 2015, there was $24.4 million of total unrecognized share-based compensation expense related to stock options that will be recognized over a weighted-average period of 1.84 years.
	Restricted Stock Units
	A summary of the RSU activity under the Company’s plans for the nine months ended March 31, 2015 is as follows:
			Number		Weighted
			of		average grant
			shares		date fair value
	RSUs outstanding at June 30, 2014			—	$	—
	RSUs granted			1,245,833	$	37.67
	Less:
	RSUs vested			19,500	$	34.22
	RSUs canceled			100,283	$	38.12
	RSUs outstanding at March 31, 2015			1,126,050	$	37.68
	The grant date fair value of an RSU equals the closing price of our common stock on the grant date. The weighted average grant date fair value of RSUs outstanding at March 31, 2015 is $37.68.
	As of March 31, 2015, there was $28.7 million of total unrecognized share-based compensation expense related to RSUs that will be recognized over a weighted-average period of 2.77 years. This unrecognized compensation expense is equal to the fair value of RSUs expected to vest.
	Employee Stock Purchase Plan
	The Company also has an Employee Stock Purchase Plan that was approved by shareholders in 2012 (the “2012 Purchase Plan”), under which 2,000,000 shares of common stock have been authorized. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period. As of March 31, 2015, approximately 334,000 shares of common stock have been issued under the 2012 Purchase Plan and approximately 1,666,000 were available for issuance.
	Share-Based Compensation Expense
	Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows:
	(In thousands)		Three months ended				Nine months ended
			March 31,				March 31,
			2015		2014		2015		2014
	Cost of molecular diagnostic testing		$	224	$	207	$	671	$	639
	Cost of pharmaceutical and clinical services			104		75		387		212
	Research and development expense			1,201		3,042		3,218		4,670
	Selling, general, and administrative expense			11,016		10,316		27,296		21,911
	Total share-based compensation expense		$	12,545	$	13,640	$	31,572	$	27,432
	In October 2014, the Company and its former Chief Financial Officer entered into a resignation agreement under which the vesting of certain awards were modified such that the specified awards were vested in full. As a result of this award modification the Company recognized approximately $3.1 million in share-based compensation expense for the nine months ending March 31, 2015.
	In February 2015, the Company and its Chief Executive Officer entered into a resignation agreement under which the vesting of certain awards were modified such that the specified awards were accelerated. As a result of this award modification the Company recognized approximately $5.2 million in share-based compensation expense for the three and nine months ending March 31, 2015.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Mar. 31, 2015
Stockholders' Equity	-4	Stockholders’ Equity
	Share Repurchase Program
	In February 2015, the Company’s Board of Directors authorized an additional share repurchase program of $200 million of the Company’s outstanding common stock increasing the cumulative share repurchase authorization to $1.2 billion. The Company plans to repurchase its common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company’s management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors. As of March 31, 2015, approximately $199.7 million remained available for repurchases under the program. The Company uses the par value method of accounting for its stock repurchases. As a result of the stock repurchases, the Company reduced common stock and additional paid-in capital and recorded charges to retained earnings. The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to retained earnings for the repurchases for the three and nine months ended March 31, 2015 and 2014 were as follows:
	(In thousands)		Three months ended				Nine months ended
			March 31,				March 31,
			2015		2014		2015		2014
	Shares purchased and retired			1,779		1,554		4,729		8,545
	Common stock and additional paid-in-capital reductions		$	15,212	$	12,384	$	40,172	$	67,420
	Charges to retained earnings		$	46,782	$	29,506	$	125,774	$	154,594

Earnings_Per_Share

Earnings Per Share	9 Months Ended
	Mar. 31, 2015
Earnings Per Share	-5	Earnings Per Share
	Basic earnings per share is computed based on the weighted-average number of shares of the Company’s common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of the Company’s common stock, including the dilutive effect of common stock equivalents outstanding.
	The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:
	(In thousands)		Three months ended				Nine months ended
			March 31,				March 31,
			2015		2014		2015		2014
	Denominator:
	Weighted-average shares outstanding used to compute basic earnings per share			70,696		73,821		71,985		76,173
	Effect of dilutive common stock equivalents			3,174		2,553		3,137		2,159
	Weighted-average shares outstanding and dilutive securities used to compute dilutive earnings per share			73,870		76,374		75,122		78,332
	Certain outstanding stock options and RSUs were excluded from the computation of diluted earnings per share for the three and nine months ended March 31, 2015 and 2014 because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:
			Three months ended				Nine months ended
			March 31,				March 31,
	(In thousands)		2015		2014		2015		2014
	Anti-dilutive options and RSUs excluded from EPS computation			52		5,300		41		6,978

Segment_and_Related_Informatio

Segment and Related Information	9 Months Ended
	Mar. 31, 2015
Segment and Related Information	-6	Segment and Related Information
	The Company’s business units have been aggregated into three reportable segments: (i) research, (ii) molecular diagnostics and (iii) pharmaceutical and clinical services. The research segment is focused on the discovery of genes, biomarkers and proteins related to major common diseases and includes corporate services such as finance, human resources, legal, and information technology. The molecular diagnostics segment provides testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The pharmaceutical and clinical services segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries. The Company evaluates segment performance based on results from operations before interest income and expense and other income and expense.
	Segment revenue and operating income (loss) were as follows during the periods presented:
	(In thousands)		Molecular			Pharmaceutical &			Research			Total
			diagnostics			clinical services
	Three months ended March 31, 2015:
	Revenue		$	172,978			7,007			—		$	179,985
	Depreciation and amortization			5,207			566			626			6,399
	Segment operating income (loss)			55,198			(1,147	)		(18,311	)		35,740
	Three months ended March 31, 2014:
	Revenue		$	176,191			6,733			—		$	182,924
	Depreciation and amortization			2,506			471			502			3,479
	Segment operating income (loss)			70,815			(73	)		(15,455	)		55,287
	Nine months ended March 31, 2015:
	Revenue		$	516,634			16,582			—		$	533,216
	Depreciation and amortization			15,176			1,465			1,748			18,389
	Segment operating income (loss)			159,299			(3,941	)		(57,356	)		98,002
	Nine months ended March 31, 2014:
	Revenue		$	565,335			24,115			—		$	589,450
	Depreciation and amortization			5,335			1,462			1,494			8,291
	Segment operating income (loss)			266,794			2,816			(48,422	)		221,188
			Three months ended						Nine months ended
			March 31,						March 31,
	(In thousands)		2015			2014			2015			2014
	Total operating income for reportable segments		$	35,740		$	55,287		$	98,002		$	221,188
	Interest income			124			2,498			265			5,190
	Other			(298	)		(442	)		1,117			(1,066	)
	Income tax provision			14,091			20,573			37,896			82,719
	Net income		$	21,475		$	36,770		$	61,488		$	142,593

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Mar. 31, 2015
Fair Value Measurements	-7	Fair Value Measurements
	The fair value of the Company’s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:
	Level 1		—		quoted prices in active markets for identical assets and liabilities.
	Level 2		—		observable inputs other than quoted prices in active markets for identical assets
					and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Some of the Company’s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.
	Level 3		—		unobservable inputs.
	All of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, the Company uses a third party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. The Company reviews, tests and validates this information. The following table sets forth the fair value of the financial assets that the Company re-measured on a regular basis:
	(In thousands)		Level 1			Level 2		Level 3		Total
	at March 31, 2015:
	Money market funds (a)		$	2,616		$	—	$	—	$	2,616
	Corporate bonds and notes			6,999			35,734		—		42,733
	Municipal bonds			—			71,616		—		71,616
	Federal agency issues			—			13,576		—		13,576
	Total		$	9,615		$	120,926	$	—	$	130,541
	(In thousands)		Level 1			Level 2		Level 3		Total
	at June 30, 2014:
	Money market funds (a)		$	13,634		$	—	$	—	$	13,634
	Corporate bonds and notes			—			44,474		—		44,474
	Municipal bonds			—			144,158		—		144,158
	Federal agency issues			—			23,139		—		23,139
	Total		$	13,634		$	211,771	$	—	$	225,405
	(a)	Money market funds are primarily comprised of exchange traded funds and accrued interest

Income_Taxes

Income Taxes	9 Months Ended
	Mar. 31, 2015
Income Taxes	-8	Income Taxes
	In order to determine the Company’s quarterly provision for income taxes, the Company used an estimated annual effective tax rate that is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rates from quarter to quarter.
	Income tax expense for the three months ended March 31, 2015 was $14.1 million, or approximately 40% of pre-tax income, compared to $20.6 million, for the three months ended March 31, 2014, or approximately 36% of pre-tax income. Income tax expense for the nine months ended March 31, 2015 was $37.9 million, or approximately 38% of pre-tax income, compared to $82.7 million, or approximately 37% of pre-tax income. Income tax expense for the three and nine months ended March 31, 2015 is based on the Company’s estimated annual effective tax rate for the full fiscal year ending June 30, 2015, adjusted by discrete items recognized during the period. For the three months ended March 31, 2015, the Company’s recognized effective tax rate differs from the U.S. federal statutory rate of 35% primarily due to the effect of state income taxes and the impact from the exclusion of certain losses incurred from our international operations offset by the benefits realized from the timing differences related to the recognition of the tax effect of equity compensation expense from incentive stock options and the deduction realized when those options are disqualified upon exercise and sale.
	The Company files U.S., foreign and state income tax returns in jurisdictions with various statutes of limitations. The Company’s New Jersey State income tax returns for the years ended June 30, 2007 through 2013 are currently under examination by the New Jersey State Department of Taxation and Finance. Annual and interim tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued. The Company’s U.S. federal tax return and other state tax returns are not currently under examination.

Acquisition

Acquisition	9 Months Ended
	Mar. 31, 2015
Acquisition	-9	Acquisition
	German Clinic
	On February 27, 2015, the Company completed the acquisition of privately-held Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG located in Germany (“Clinic”) approximately 15 miles from the Company’s European laboratories. The cash paid and preliminary total consideration transferred to acquire the Clinic was $20.1 million.
	Total consideration transferred was allocated to tangible and identifiable intangible assets acquired and liabilities assumed based on their preliminary fair values at the acquisition date as set forth below. The Company believes acquisition of the Clinic may facilitate the Company’s penetration into the German molecular diagnostic market. The Clinic will allow the Company to directly negotiate reimbursement with government and private insurance providers in the German market and collaborate with hospitals and physician groups. These factors contributed to consideration transferred in excess of the fair value of the Clinic’s net tangible and intangible assets acquired, resulting in the Company recording goodwill in connection with the transaction. Under German tax law the goodwill related to the purchase of the clinic is deductible and will be amortized for tax purposes over 15 years. Management estimated the fair values of tangible and intangible asset and liabilities in accordance with the applicable accounting guidance for business combinations and utilized the services of third-party valuation consultants. The preliminary allocation of the consideration transferred is subject to potential adjustments primarily due to tax-related matters, including tax basis of acquired assets and liabilities in the foreign jurisdiction, and third party valuations of acquired assets and liabilities, including deferred grants and actuarial analysis of pension assets and liabilities. During the measurement period, the Company may record adjustments to the provisional amounts recognized in the Company’s initial accounting for the acquisition. The Company expects the allocation of the consideration transferred to be final within the measurement period (up to one year from the acquisition date).
	(in thousands)		Estimated Fair
			Value
	Current assets		$	3,078
	Real property			20,715
	Equipment			1,625
	Other assets			43
	Goodwill			16,576
	Current liabilities			(4,412	)
	Long-term liabilities			(6,672	)
	Deferred grants			(10,838	)
	Total purchase price		$	20,115
	The Clinic has received subsidies from the German government for assets that were previously purchased. These subsidies are recorded in deferred grants currently totaling $10.4 million as of March 31, 2015. The recognition of revenue relating to the subsidies occurs ratably over the useful life of the related assets.
	The unaudited condensed consolidated financial statements include the operating results of the Clinic in the pharmaceutical and clinical services segment from the date of acquisition. Pro forma results of operations have not been presented as the Clinic’s prior-period financial results are not considered material to the Company.
	Crescendo Bioscience, Inc.
	On February 28, 2014, the Company completed the acquisition of privately-held Crescendo Bioscience, Inc. (“Crescendo”), pursuant to an Amended and Restated Agreement and Plan of Merger, dated February 2, 2014 (the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, Myriad acquired Crescendo for total consideration of $259.0 million.
	The following table reconciles consideration transferred to the total cash paid to acquire Crescendo:
	(In thousands)
	Total consideration transferred		$	258,950
	Share-based compensation to Crescendo employees			6,929
	Change of control payments to Crescendo employees			5,695
	Offset: Non-cash fair value purchase option			(8,000	)
	Total cash paid		$	263,574
	The total consideration of $259 million consisted of (i) $225.1 million in cash, (ii) $25.9 million in elimination of intercompany balances related to accrued interest and the term loan the Company issued to Crescendo on September 8, 2011, and (iii) $8 million related to the fair value of the purchase option granted to the Company on September 8, 2011 by Crescendo through a definitive merger agreement (“Option Agreement”) entered into in association with the term note. Of the cash consideration, $20 million was deposited into an escrow account to fund (i) any post-closing adjustments payable to Myriad based upon differences between the estimated working capital and the actual working capital of Crescendo at closing, and (ii) any indemnification claims made by Myriad against Crescendo, for a period of time, based upon the completion of an audit of Crescendo’s financial statements, of no fewer than twelve nor more than fifteen months following closing.
	Of the total cash paid, $6.9 million was accounted for as share-based compensation expense resulting from the accelerated vesting of employee options immediately prior to the acquisition and $5.7 million was accounted for as change of control bonuses paid to Crescendo employees and directors. The Company recognized the share-based compensation expense and change of control bonuses in post-acquisition consolidated statements of comprehensive income for the year ended June 30, 2014.
	Total consideration transferred was allocated to tangible and identifiable intangible assets acquired and liabilities assumed based on their preliminary fair values at the acquisition date as set forth below. The Company believes that the acquisition of Crescendo facilitates the Company’s entry into the high growth autoimmune market, diversifies its product revenue and enhances its strength in protein-based diagnostics. These factors contributed to consideration transferred in excess of the fair value of Crescendo’s net tangible and intangible assets acquired, resulting in the Company recording goodwill in connection with the transaction.
	The Company’s allocation of consideration transferred for Crescendo is as follows:
	(In thousands)		Estimated
			Fair Value
	Other assets acquired		$	15,826
	Intangible assets			196,600
	Goodwill			112,331
	Total assets acquired			324,757
	Deferred tax liability			44,213
	Other liabilities assumed			21,594
	Total net assets acquired		$	258,950
	Pro Forma Information
	The unaudited pro-forma results presented below include the effects of the Crescendo acquisition as if it had been consummated as of July 1, 2013, with adjustments to give effect to pro forma events that are directly attributable to the acquisition which includes adjustments related to the amortization of acquired intangible assets, interest income and expense, stock-based compensation expense, and depreciation. The unaudited pro forma results do not reflect any operating efficiency or potential cost savings which may result from the consolidation of Crescendo. Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operation of the combined company would have been if the acquisition had occurred at the beginning of the period presented nor are they indicative of future results of operations and are not necessarily indicative of either future results of operations or results that might have been achieved had the acquisition been consummated as of July 1, 2013.
	(In thousands)		Three months ended					Nine months ended
			March 31,					March 31,
			2015			2014		2015		2014
	Revenue		$	179,985		$	188,693	$	533,216	$	618,743
	Income from operations		$	35,740		$	47,396	$	98,002	$	199,380
	Net income		$	21,475		$	29,173	$	61,488	$	122,316
	Net income per share, basic		$	0.3		$	0.4	$	0.85	$	1.61
	Net income per share, diluted		$	0.29		$	0.38	$	0.82	$	1.56

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	9 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets	-10	Goodwill and Intangible Assets
	Goodwill
	The following summary sets forth the changes in goodwill for the nine months ended March 31, 2015:
	(In thousands)		Gross
			Carrying
			Amount
	Beginning balance at June 30, 2014		$	169,181
	Acquisition of the clinic			16,576
	Translation adjustments			(529	)
	Ending balance at March 31, 2015			185,228
	At March 31, 2015, the Company had recorded goodwill of $185.2 million, net of translation adjustments, related to the acquisitions of Myriad RBM, Inc. on May 31, 2011 (formerly Rules-Based Medicine, Inc.), Crescendo on February 28, 2014 and the Clinic on February 27, 2015.
	Intangible Assets
	Intangible assets primarily consist of amortizable assets of purchased licenses and technologies, customer relationships, and trade names as well as non-amortizable intangible assets of in-process technologies and research and development. The following summarizes the amounts reported as intangible assets:
	(In thousands)		Gross			Accumulated
			Carrying
	March 31, 2015:		Amount			Amortization			Net
	Purchased licenses and technologies		$	199,100		$	(13,719	)	$	185,381
	Customer relationships			4,650			(1,790	)		2,860
	Trademarks			3,000			(350	)		2,650
	Total amortizable intangible assets			206,750			(15,859	)		190,891
	In-process research and development			4,800			—			4,800
	Total non-amortizable intangible assets			4,800			—			4,800
	Total intangible assets		$	211,550		$	(15,859	)	$	195,691
	(In thousands)		Gross			Accumulated
			Carrying
	June 30, 2014:		Amount			Amortization			Net
	Purchased licenses and technologies		$	201,100		$	(6,597	)	$	194,503
	Customer relationships			4,650			(1,441	)		3,209
	Trademarks			3,000			(200	)		2,800
	Total amortizable intangible assets			208,750			(8,238	)		200,512
	In-process research and development			4,800			—			4,800
	Total non-amortizable intangible assets			4,800			—			4,800
	Total intangible assets		$	213,550		$	(8,238	)	$	205,312
	The Company recorded amortization expense during the respective periods for these intangible assets as follows:
	(In thousands)		Three months ended						Nine months ended
			March 31,						March 31,
			2015			2014			2015		2014
	Amortization of intangible assets		$	3,136		$	1,146		$	9,621	$	1,634

Cost_Basis_Investment

Cost Basis Investment	9 Months Ended
	Mar. 31, 2015
Cost Basis Investment	-11	Cost Basis Investment
	As of March 31, 2015, the Company had a $5.0 million investment in RainDance Technologies, Inc., which has been recorded under the cost method as an “Other Asset” on the Company’s condensed consolidated balance sheet. There were no events or circumstances that indicated that impairment exists; therefore, the Company recorded no impairment in the investment for the nine months ended March 31, 2015.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2015
Commitments and Contingencies	-12	Commitments and Contingencies
	The Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. As of March 31, 2015, the management of the Company believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, operating results, or cash flows.

Marketable_Investment_Securiti1

Marketable Investment Securities (Tables)	9 Months Ended
	Mar. 31, 2015
Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security	The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at March 31, 2015 and June 30, 2014 were as follows:
	(In thousands)	Amortized		Gross		Gross			Estimated
		cost		unrealized		unrealized			fair value
				holding		holding
				gains		losses
	At March 31, 2015:
	Cash and cash equivalents:
	Cash	$	45,092	$	—	$	—		$	45,092
	Cash equivalents		10,117		—		—			10,117
	Total cash and cash equivalents		55,209		—		—			55,209
	Available-for-sale securities:
	Corporate bonds and notes		35,733		12		(11	)		35,734
	Municipal bonds		71,534		104		(22	)		71,616
	Federal agency issues		13,074		1		(1	)		13,074
	Total available-for-sale securities		120,341		117		(34	)		120,424
	Total cash, cash equivalents
	and available-for-sale securities	$	175,550	$	117	$	(34	)	$	175,633
	(In thousands)	Amortized		Gross		Gross			Estimated
		cost		unrealized		unrealized			fair value
				holding		holding
				gains		losses
	At June 30, 2014:
	Cash and cash equivalents:
	Cash	$	45,181	$	—	$	—		$	45,181
	Cash equivalents		19,639		1		—			19,640
	Total cash and cash equivalents		64,820		1		—			64,821
	Available-for-sale securities:
	Corporate bonds and notes		44,449		36		(11	)		44,474
	Municipal bonds		137,821		334		(3	)		138,152
	Federal agency issues		23,134		12		(7	)		23,139
	Total available-for-sale securities		205,404		382		(21	)		205,765
	Total cash, cash equivalents
	and available-for-sale securities	$	270,224	$	383	$	(21	)	$	270,586
Schedule of Maturities of Debt Securities Classified as Cash Equivalents and Available-For-Sale	Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities are as follows at March 31, 2015:
	(In thousands)	Amortized		Estimated
		cost		fair value
	Cash	$	45,092	$	45,092
	Cash equivalents		10,117		10,117
	Available-for-sale:
	Due within one year		79,200		79,224
	Due after one year through five years		41,141		41,200
	Due after five years		—		—
		$	175,550	$	175,633

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	9 Months Ended
	Mar. 31, 2015
Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding	A summary of the stock option activity under the Company’s plans for the nine months ended March 31, 2015 is as follows:
		Number of		Weighted
		shares		average
				exercise
				price
	Options outstanding at June 30, 2014		14,238,183	$	23.3
	Options granted		1,000	$	37.17
	Less:
	Options exercised		1,144,275	$	20.2
	Options canceled or expired		343,161	$	25.7
	Options outstanding at March 31, 2015		12,751,747	$	23.51
Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding	A summary of the RSU activity under the Company’s plans for the nine months ended March 31, 2015 is as follows:
		Number		Weighted
		of		average grant
		shares		date fair value
	RSUs outstanding at June 30, 2014		—	$	—
	RSUs granted		1,245,833	$	37.67
	Less:
	RSUs vested		19,500	$	34.22
	RSUs canceled		100,283	$	38.12
	RSUs outstanding at March 31, 2015		1,126,050	$	37.68
Schedule of Share-Based Compensation Recognized in Consolidated Statements of Income and Comprehensive Income	Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows:
	(In thousands)	Three months ended				Nine months ended
		March 31,				March 31,
		2015		2014		2015		2014
	Cost of molecular diagnostic testing	$	224	$	207	$	671	$	639
	Cost of pharmaceutical and clinical services		104		75		387		212
	Research and development expense		1,201		3,042		3,218		4,670
	Selling, general, and administrative expense		11,016		10,316		27,296		21,911
	Total share-based compensation expense	$	12,545	$	13,640	$	31,572	$	27,432

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Mar. 31, 2015
Schedule of Stock Repurchases	The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to retained earnings for the repurchases for the three and nine months ended March 31, 2015 and 2014 were as follows:
	(In thousands)	Three months ended				Nine months ended
		March 31,				March 31,
		2015		2014		2015		2014
	Shares purchased and retired		1,779		1,554		4,729		8,545
	Common stock and additional paid-in-capital reductions	$	15,212	$	12,384	$	40,172	$	67,420
	Charges to retained earnings	$	46,782	$	29,506	$	125,774	$	154,594

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Mar. 31, 2015
Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations	The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:
	(In thousands)	Three months ended				Nine months ended
		March 31,				March 31,
		2015		2014		2015		2014
	Denominator:
	Weighted-average shares outstanding used to compute basic earnings per share		70,696		73,821		71,985		76,173
	Effect of dilutive common stock equivalents		3,174		2,553		3,137		2,159
	Weighted-average shares outstanding and dilutive securities used to compute dilutive earnings per share		73,870		76,374		75,122		78,332
Schedule of Anti-Dilutive Options and Restricted Stock Units Excluded from EPS Computation	These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:
		Three months ended				Nine months ended
		March 31,				March 31,
	(In thousands)	2015		2014		2015		2014
	Anti-dilutive options and RSUs excluded from EPS computation		52		5,300		41		6,978

Segment_and_Related_Informatio1

Segment and Related Information (Tables)	9 Months Ended
	Mar. 31, 2015
Segment Revenue and Operating Income (Loss)	Segment revenue and operating income (loss) were as follows during the periods presented:
	(In thousands)	Molecular			Pharmaceutical &			Research			Total
		diagnostics			clinical services
	Three months ended March 31, 2015:
	Revenue	$	172,978			7,007			—		$	179,985
	Depreciation and amortization		5,207			566			626			6,399
	Segment operating income (loss)		55,198			(1,147	)		(18,311	)		35,740
	Three months ended March 31, 2014:
	Revenue	$	176,191			6,733			—		$	182,924
	Depreciation and amortization		2,506			471			502			3,479
	Segment operating income (loss)		70,815			(73	)		(15,455	)		55,287
	Nine months ended March 31, 2015:
	Revenue	$	516,634			16,582			—		$	533,216
	Depreciation and amortization		15,176			1,465			1,748			18,389
	Segment operating income (loss)		159,299			(3,941	)		(57,356	)		98,002
	Nine months ended March 31, 2014:
	Revenue	$	565,335			24,115			—		$	589,450
	Depreciation and amortization		5,335			1,462			1,494			8,291
	Segment operating income (loss)		266,794			2,816			(48,422	)		221,188
		Three months ended						Nine months ended
		March 31,						March 31,
	(In thousands)	2015			2014			2015			2014
	Total operating income for reportable segments	$	35,740		$	55,287		$	98,002		$	221,188
	Interest income		124			2,498			265			5,190
	Other		(298	)		(442	)		1,117			(1,066	)
	Income tax provision		14,091			20,573			37,896			82,719
	Net income	$	21,475		$	36,770		$	61,488		$	142,593

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Mar. 31, 2015
Schedule of Fair Value of Financial Assets	The following table sets forth the fair value of the financial assets that the Company re-measured on a regular basis:
	(In thousands)		Level 1		Level 2		Level 3		Total
	at March 31, 2015:
	Money market funds (a)		$	2,616	$	—	$	—	$	2,616
	Corporate bonds and notes			6,999		35,734		—		42,733
	Municipal bonds			—		71,616		—		71,616
	Federal agency issues			—		13,576		—		13,576
	Total		$	9,615	$	120,926	$	—	$	130,541
	(In thousands)		Level 1		Level 2		Level 3		Total
	at June 30, 2014:
	Money market funds (a)		$	13,634	$	—	$	—	$	13,634
	Corporate bonds and notes			—		44,474		—		44,474
	Municipal bonds			—		144,158		—		144,158
	Federal agency issues			—		23,139		—		23,139
	Total		$	13,634	$	211,771	$	—	$	225,405
	(a)	Money market funds are primarily comprised of exchange traded funds and accrued interest

Acquisition_Tables

Acquisition (Tables)	9 Months Ended
	Mar. 31, 2015
Allocation of Consideration Transferred	The Company expects the allocation of the consideration transferred to be final within the measurement period (up to one year from the acquisition date).
	(in thousands)	Estimated Fair
		Value
	Current assets	$	3,078
	Real property		20,715
	Equipment		1,625
	Other assets		43
	Goodwill		16,576
	Current liabilities		(4,412	)
	Long-term liabilities		(6,672	)
	Deferred grants		(10,838	)
	Total purchase price	$	20,115
Reconciliation of Consideration Transferred to Total Cash Paid to Acquire Business	The following table reconciles consideration transferred to the total cash paid to acquire Crescendo:
	(In thousands)
	Total consideration transferred	$	258,950
	Share-based compensation to Crescendo employees		6,929
	Change of control payments to Crescendo employees		5,695
	Offset: Non-cash fair value purchase option		(8,000	)
	Total cash paid	$	263,574
Allocation of Consideration Transferred for Crescendo	The Company’s allocation of consideration transferred for Crescendo is as follows:
	(In thousands)	Estimated
		Fair Value
	Other assets acquired	$	15,826
	Intangible assets		196,600
	Goodwill		112,331
	Total assets acquired		324,757
	Deferred tax liability		44,213
	Other liabilities assumed		21,594
	Total net assets acquired	$	258,950
Pro-forma Results of Acquisitions	The unaudited pro-forma results presented below include the effects of the Crescendo acquisition as if it had been consummated as of July 1, 2013, with adjustments to give effect to pro forma events that are directly attributable to the acquisition which includes adjustments related to the amortization of acquired intangible assets, interest income and expense, stock-based compensation expense, and depreciation. The unaudited pro forma results do not reflect any operating efficiency or potential cost savings which may result from the consolidation of Crescendo. Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operation of the combined company would have been if the acquisition had occurred at the beginning of the period presented nor are they indicative of future results of operations and are not necessarily indicative of either future results of operations or results that might have been achieved had the acquisition been consummated as of July 1, 2013.
	(In thousands)	Three months ended					Nine months ended
		March 31,					March 31,
		2015			2014		2015		2014
	Revenue	$	179,985		$	188,693	$	533,216	$	618,743
	Income from operations	$	35,740		$	47,396	$	98,002	$	199,380
	Net income	$	21,475		$	29,173	$	61,488	$	122,316
	Net income per share, basic	$	0.3		$	0.4	$	0.85	$	1.61
	Net income per share, diluted	$	0.29		$	0.38	$	0.82	$	1.56

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Mar. 31, 2015
Changes in Carrying Amount of Goodwill	The following summary sets forth the changes in goodwill for the nine months ended March 31, 2015:
	(In thousands)	Gross
		Carrying
		Amount
	Beginning balance at June 30, 2014	$	169,181
	Acquisition of the clinic		16,576
	Translation adjustments		(529	)
	Ending balance at March 31, 2015		185,228
Summarized Amounts Reported as Intangible Assets	The following summarizes the amounts reported as intangible assets:
	(In thousands)	Gross			Accumulated
		Carrying
	March 31, 2015:	Amount			Amortization			Net
	Purchased licenses and technologies	$	199,100		$	(13,719	)	$	185,381
	Customer relationships		4,650			(1,790	)		2,860
	Trademarks		3,000			(350	)		2,650
	Total amortizable intangible assets		206,750			(15,859	)		190,891
	In-process research and development		4,800			—			4,800
	Total non-amortizable intangible assets		4,800			—			4,800
	Total intangible assets	$	211,550		$	(15,859	)	$	195,691
	(In thousands)	Gross			Accumulated
		Carrying
	June 30, 2014:	Amount			Amortization			Net
	Purchased licenses and technologies	$	201,100		$	(6,597	)	$	194,503
	Customer relationships		4,650			(1,441	)		3,209
	Trademarks		3,000			(200	)		2,800
	Total amortizable intangible assets		208,750			(8,238	)		200,512
	In-process research and development		4,800			—			4,800
	Total non-amortizable intangible assets		4,800			—			4,800
	Total intangible assets	$	213,550		$	(8,238	)	$	205,312
Amortization for Intangible Assets	The Company recorded amortization expense during the respective periods for these intangible assets as follows:
	(In thousands)	Three months ended						Nine months ended
		March 31,						March 31,
		2015			2014			2015		2014
	Amortization of intangible assets	$	3,136		$	1,146		$	9,621	$	1,634

Basis_of_Presentation_Addition

Basis of Presentation - Additional Information (Detail) (USD $)	12 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2014
Trade Accounts Receivable
Organization and Summary of Significant Accounting Policies Disclosure [Line Items]
Prior period reclassification adjustment	$0.60
Foreign Exchange
Organization and Summary of Significant Accounting Policies Disclosure [Line Items]
Prior period reclassification adjustment		1
Maturities and Sales of Marketable Securities
Organization and Summary of Significant Accounting Policies Disclosure [Line Items]
Prior period reclassification adjustment		-1
Other Receivables
Organization and Summary of Significant Accounting Policies Disclosure [Line Items]
Prior period reclassification adjustment	($0.60)

Marketable_Investment_Securiti2

Marketable Investment Securities - Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Detail) (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$175,550	$270,224
Gross unrealized holding gains	117	383
Gross unrealized holding losses	-34	-21
Estimated fair value	175,633	270,586
Cash
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	45,092	45,181
Estimated fair value	45,092	45,181
Cash Equivalents
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	10,117	19,639
Gross unrealized holding gains		1
Estimated fair value	10,117	19,640
Total Cash And Cash Equivalents
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	55,209	64,820
Gross unrealized holding gains		1
Estimated fair value	55,209	64,821
Corporate Bonds And Notes
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	35,733	44,449
Gross unrealized holding gains	12	36
Gross unrealized holding losses	-11	-11
Estimated fair value	35,734	44,474
Municipal Bonds
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	71,534	137,821
Gross unrealized holding gains	104	334
Gross unrealized holding losses	-22	-3
Estimated fair value	71,616	138,152
Federal Agency Issues
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	13,074	23,134
Gross unrealized holding gains	1	12
Gross unrealized holding losses	-1	-7
Estimated fair value	13,074	23,139
Total Available For Sale
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	120,341	205,404
Gross unrealized holding gains	117	382
Gross unrealized holding losses	-34	-21
Estimated fair value	$120,424	$205,765

Marketable_Investment_Securiti3

Marketable Investment Securities - Schedule of Maturities of Debt Securities Classified as Cash Equivalents and Available-For-Sale (Detail) (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$175,550	$270,224
Due within one year, Amortized cost	79,200
Due after one year through five years, Amortized cost	41,141
Due after five years, Amortized cost	0
Total	175,550
Estimated fair value	175,633	270,586
Due within one year, Estimated fair value	79,224
Due after one year through five years, Estimated fair value	41,200
Due after five years, Estimated fair value	0
Total	175,633
Cash
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	45,092	45,181
Estimated fair value	45,092	45,181
Cash Equivalents
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	10,117	19,639
Estimated fair value	$10,117	$19,640

ShareBased_Compensation_Additi

Share-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended		1 Months Ended	6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Sep. 30, 2014	Mar. 31, 2015	Dec. 05, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options to purchase shares vested and exercisable, shares	8,935,850		8,935,850			8,935,850
Exercisable weighted average price of options	$22.55		$22.55			22.55
Total unrecognized share-based compensation cost related to stock options	$24,400,000		$24,400,000			24,400,000
Total unrecognized share-based compensation cost related to RSUs	28,700,000		28,700,000			28,700,000
RSUs outstanding at at end of period, Weighted average grant date fair value	$37.68		$37.68			37.68
Share based compensation expense	12,545,000	13,640,000	31,572,000	27,432,000
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Service period of share-based compensation vested, years					4 years
Total unrecognized share-based compensation cost, weighted-average period, years			2 years 9 months 7 days
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Service period of share-based compensation vested, years			4 years
Total unrecognized share-based compensation cost, weighted-average period, years			1 year 10 months 2 days
Stock options | Share-based compensation granted after December 5, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expire from date of grant, years			8 years
Stock options | Share-based compensation granted prior to December 5, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expire from date of grant, years			10 years
2012 Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares approved	2,000,000		2,000,000			2,000,000
Shares reserved for issuance exercise of options	1,666,000		1,666,000			1,666,000
Shares issued under the Plan			334,000
The 2010 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares approved							3,500,000
Shares reserved for issuance exercise of options	1,801,462		1,801,462			1,801,462
The 2010 Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grant						4,400,795
Chief Financial Officer [Member] | Resignation Agreement In February Two Thousand Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation expense	5,200,000		5,200,000
Chief Financial Officer [Member] | Resignation Agreement In October Two Thousand Fourteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation expense			$3,100,000

ShareBased_Compensation_Schedu

Share-Based Compensation - Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding (Detail) (USD $)	9 Months Ended
	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding at beginning of period, Number of shares	14,238,183
Options granted, Number of shares	1,000
Options exercised, Number of shares	1,144,275
Options canceled or expired, Number of shares	343,161
Options outstanding at end of period, Number of shares	12,751,747
Options outstanding at beginning of period, Weighted average exercise price	$23.30
Options granted, Weighted average exercise price	$37.17
Options exercised, Weighted average exercise price	$20.20
Options canceled or expired, Weighted average exercise price	$25.70
Options outstanding at end of period, Weighted average exercise price	$23.51

ShareBased_Compensation_Schedu1

Share-Based Compensation - Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding (Detail) (USD $)	9 Months Ended
	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSUs granted, Number of shares	1,245,833
RSUs vested, Number of shares	19,500
RSUs canceled, Number of shares	100,283
RSUs outstanding at end of period, Number of shares	1,126,050
RSUs granted, Weighted average grant date fair value	$37.67
RSUs vested, Weighted average grant date fair value	$34.22
RSUs canceled, Weighted average grant date fair value	$38.12
RSUs outstanding at at end of period, Weighted average grant date fair value	$37.68

ShareBased_Compensation_Schedu2

Share-Based Compensation - Schedule of Share-Based Compensation Recognized in Consolidated Statements of Income and Comprehensive Income (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$12,545	$13,640	$31,572	$27,432
Molecular Diagnostic Testing Expense
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	224	207	671	639
Pharmaceutical and Clinical Services Expense
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	104	75	387	212
Research And Development Expense
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	1,201	3,042	3,218	4,670
Selling, General, and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$11,016	$10,316	$27,296	$21,911

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	Mar. 31, 2015	Feb. 28, 2015
Stockholders Equity Note [Line Items]
Additional share repurchase program, authorized amount		$200,000,000
Cumulative share repurchase, authorized amount		1,200,000,000
Share repurchase program, remaining authorized repurchase amount	$199,700,000

Stockholders_Equity_Schedule_o

Stockholders' Equity - Schedule of Stock Repurchases (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Stockholders Equity [Line Items]
Common stock and additional paid-in-capital reductions	$15,212	$12,384	$40,172	$67,420
Charges to retained earnings	$46,782	$29,506	$125,774	$154,594
Common Stock
Stockholders Equity [Line Items]
Shares purchased and retired	1,779	1,554	4,729	8,545

Earnings_Per_Share_Reconciliat

Earnings Per Share - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Detail)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Schedule of Earnings Per Share, Basic and Diluted, by Common Class [Line Items]
Weighted-average shares outstanding used to compute basic earnings per share	70,696	73,821	71,985	76,173
Effect of dilutive common stock equivalents	3,174	2,553	3,137	2,159
Weighted-average shares outstanding and dilutive securities used to compute dilutive earnings per share	73,870	76,374	75,122	78,332

Earnings_Per_Share_Schedule_of

Earnings Per Share - Schedule of Anti-Dilutive Options and Restricted Stock Units Excluded from EPS Computation (Detail)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive options and RSUs excluded from EPS computation	52	5,300	41	6,978

Segment_and_Related_Informatio2

Segment and Related Information - Additional Information (Detail)	9 Months Ended
	Mar. 31, 2015
	Segment
Segment Reporting Information [Line Items]
Number of reportable segment	3

Segment_and_Related_Informatio3

Segment and Related Information - Segment Performance Based on Income (Loss) before Interest Income and Other Income and Expense (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting Information [Line Items]
Revenue	$179,985	$182,924	$533,216	$589,450
Depreciation and amortization	6,399	3,479	18,389	8,291
Segment operating income (loss)	35,740	55,287	98,002	221,188
Molecular Diagnostics
Segment Reporting Information [Line Items]
Revenue	172,978	176,191	516,634	565,335
Depreciation and amortization	5,207	2,506	15,176	5,335
Segment operating income (loss)	55,198	70,815	159,299	266,794
Pharmaceutical and Clinical Services
Segment Reporting Information [Line Items]
Revenue	7,007	6,733	16,582	24,115
Depreciation and amortization	566	471	1,465	1,462
Segment operating income (loss)	-1,147	-73	-3,941	2,816
Research
Segment Reporting Information [Line Items]
Depreciation and amortization	626	502	1,748	1,494
Segment operating income (loss)	($18,311)	($15,455)	($57,356)	($48,422)

Segment_and_Related_Informatio4

Segment and Related Information - Schedule of Total Operating Income for Continuing Reportable Segments (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting Information [Line Items]
Total operating income for reportable segments	$35,740	$55,287	$98,002	$221,188
Interest income	124	2,498	265	5,190
Other	-298	-442	1,117	-1,066
Income tax provision	14,091	20,573	37,896	82,719
Net income	$21,475	$36,770	$61,488	$142,593

Fair_Value_Measurements_Schedu

Fair Value Measurements - Schedule of Fair Value of Financial Assets (Detail) (USD $)	Mar. 31, 2015		Jun. 30, 2014
In Thousands, unless otherwise specified
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets	$130,541		$225,405
Money Market Funds
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets	2,616	[1]	13,634	[1]
Corporate Bonds And Notes
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets	42,733		44,474
Municipal Bonds
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets	71,616		144,158
Federal Agency Issues
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets	13,576		23,139
Level 1
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets	9,615		13,634
Level 1 | Money Market Funds
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets	2,616	[1]	13,634	[1]
Level 1 | Corporate Bonds And Notes
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets	6,999
Level 2
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets	120,926		211,771
Level 2 | Corporate Bonds And Notes
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets	35,734		44,474
Level 2 | Municipal Bonds
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets	71,616		144,158
Level 2 | Federal Agency Issues
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets	$13,576		$23,139
[1]	Money market funds are primarily comprised of exchange traded funds and accrued interest

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Income Taxes [Line Items]
Income tax expense	$14,091	$20,573	$37,896	$82,719
Approximate rate on pre-tax income	40.00%	36.00%	38.00%	37.00%
U.S. federal statutory rate	35.00%

Acquisition_Additional_Informa

Acquisition - Additional Information (Detail) (USD $)	9 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Feb. 28, 2014	Feb. 27, 2015
Business Acquisition [Line Items]
Deferred grants	$10,447,000
Business acquisition, cash transferred	20,115,000	223,531,000
Crescendo Biosciences, Inc.
Business Acquisition [Line Items]
Total consideration transferred			258,950,000
Business acquisition, cash transferred			225,100,000
Elimination of intercompany balances related to accrued interest and term loan			25,900,000
Fair value of purchase option granted			8,000,000
Business acquisition, amount deposited into escrow account			20,000,000
Share-based compensation to Crescendo employees			6,929,000
Control bonuses paid to Crescendo employees			5,695,000
Crescendo Biosciences, Inc. | Minimum
Business Acquisition [Line Items]
Period of audit completion			12 months
Crescendo Biosciences, Inc. | Maximum
Business Acquisition [Line Items]
Period of audit completion			15 months
German Clinic [Member]
Business Acquisition [Line Items]
Total consideration transferred				20,100,000
Intangible asset amortization period for income tax purposes	15 years
Deferred grants	$10,400,000

Acquisition_Allocation_of_Cons

Acquisition - Allocation of Consideration Transferred (Detail) (USD $)	Mar. 31, 2015	Jun. 30, 2014	Feb. 27, 2015
In Thousands, unless otherwise specified
Business Acquisition [Line Items]
Goodwill	$185,228	$169,181
German Clinic [Member]
Business Acquisition [Line Items]
Current assets			3,078
Real property			20,715
Equipment			1,625
Other assets			43
Goodwill			16,576
Current liabilities			-4,412
Long-term liabilities			-6,672
Deferred grants			-10,838
Total purchase price			$20,115

Acquisition_Reconciliation_of_

Acquisition - Reconciliation of Consideration Transferred to Total Cash Paid to Acquire Business (Detail) (Crescendo Biosciences, Inc., USD $)	0 Months Ended
In Thousands, unless otherwise specified	Feb. 28, 2014
Crescendo Biosciences, Inc.
Schedule of Business Acquisitions, Cost of Acquired Entity [Line Items]
Total consideration transferred	$258,950
Share-based compensation to Crescendo employees	6,929
Change of control payments to Crescendo employees	5,695
Offset: Non-cash fair value purchase option	-8,000
Total cash paid	$263,574

Acquisition_Allocation_of_Cons1

Acquisition - Allocation of Consideration Transferred for Crescendo (Detail) (USD $)	Mar. 31, 2015	Jun. 30, 2014	Feb. 28, 2014
In Thousands, unless otherwise specified
Business Acquisition [Line Items]
Goodwill	$185,228	$169,181
Crescendo Biosciences, Inc.
Business Acquisition [Line Items]
Other assets acquired			15,826
Intangible assets			196,600
Goodwill			112,331
Total assets acquired			324,757
Deferred tax liability			44,213
Other liabilities assumed			21,594
Total net assets acquired			$258,950

Acquisition_Proforma_Results_o

Acquisition - Pro-forma Results of Acquisitions (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Business Acquisition, Pro Forma Information [Line Items]
Revenue	$179,985	$188,693	$533,216	$618,743
Income from operations	35,740	47,396	98,002	199,380
Net income	$21,475	$29,173	$61,488	$122,316
Net income per share, basic	$0.30	$0.40	$0.85	$1.61
Net income per share, diluted	$0.29	$0.38	$0.82	$1.56

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets - Additional Information (Detail) (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, unless otherwise specified
Goodwill And Intangible Assets [Line Items]
Goodwill	$185,228	$169,181

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Goodwill [Line Items]
Beginning balance	$169,181
Acquisition of the clinic	16,576
Translation adjustments	-529
Ending balance	$185,228

Goodwill_and_Intangible_Assets4

Goodwill and Intangible Assets - Summarized Amounts Reported as Intangible Assets (Detail) (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, unless otherwise specified
Intangible Assets [Line Items]
Gross Carrying Amount, total intangible assets	$211,550	$213,550
Gross Carrying Amount, amortizable intangible assets	206,750	208,750
Accumulated Amortization	-15,859	-8,238
Net, total intangible assets	195,691	205,312
Net, amortizable intangible assets	190,891	200,512
Net, non-amortizable intangible assets	4,800	4,800
In-Process Research And Development
Intangible Assets [Line Items]
Net, non-amortizable intangible assets	4,800	4,800
Purchased Licenses And Technologies
Intangible Assets [Line Items]
Gross Carrying Amount, amortizable intangible assets	199,100	201,100
Accumulated Amortization	-13,719	-6,597
Net, amortizable intangible assets	185,381	194,503
Customer Relationships
Intangible Assets [Line Items]
Gross Carrying Amount, amortizable intangible assets	4,650	4,650
Accumulated Amortization	-1,790	-1,441
Net, amortizable intangible assets	2,860	3,209
Trademarks
Intangible Assets [Line Items]
Gross Carrying Amount, amortizable intangible assets	3,000	3,000
Accumulated Amortization	-350	-200
Net, amortizable intangible assets	$2,650	$2,800

Goodwill_and_Intangible_Assets5

Goodwill and Intangible Assets - Amortization on Intangible Assets (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$3,136	$1,146	$9,621	$1,634

Cost_Basis_Investment_Addition

Cost Basis Investment - Additional Information (Detail) (USD $)	9 Months Ended
	Mar. 31, 2015
Schedule of Cost-method Investments [Line Items]
Investment accounted under cost method	$5,000,000
Impairment on investment	$0